AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark

Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.